
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 2 | 30 | 28 |
Shares | 98 | 99 | 1 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 13 | 12 |
Price to Book | 2 | 1 |
Price to Sales | 1 | 1 |
Price to Cash Flow | 6 | 6 |
Dividend Yield | 4 | 4 |
5 Years Earnings Growth | 8 | 9 |
Name | Net % | Category Average |
---|---|---|
Industrials | 19 | 15 |
Financial Services | 15 | 23 |
Healthcare | 12 | 13 |
Consumer Cyclical | 10 | 8 |
Technology | 10 | 6 |
Basic Materials | 7 | 6 |
Communication Services | 7 | 6 |
Utilities | 7 | 4 |
Consumer Defensive | 6 | 10 |
Energy | 3 | 7 |
Real Estate | 3 | 2 |
Number of long holdings: 180
Number of short holdings: 34
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
ASML Holding | NL0010273215 | 3.63 | 625.30 | +1.31% | |
Novo Nordisk B | DK0062498333 | 2.64 | 364.7 | +1.73% | |
Fresenius SE | DE0005785604 | 2.22 | 46.520 | +0.04% | |
Deutsche Telekom AG | DE0005557508 | 2.14 | 31.110 | -0.92% | |
Siemens Healthineers | DE000SHL1006 | 2.13 | 46.66 | +0.86% | |
Heidelberg Materials | DE0006047004 | 2.10 | 191.900 | -2.34% | |
SAP | DE0007164600 | 2.05 | 231.350 | +1.80% | |
BASF | DE000BASF111 | 1.93 | 44.630 | -0.62% | |
Iberdrola | ES0144580Y14 | 1.93 | 15.800 | -0.06% | |
Safran | FR0000073272 | 1.83 | 281.60 | +0.75% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
FR0010501858 | 1.82B | -0.96 | 10.74 | 11.19 | ||
CPR USA I | 1.82B | -0.64 | 11.59 | 11.87 | ||
CPR USA O | 1.82B | -0.38 | 12.11 | 12.38 | ||
FR0010917658 | 1.19B | 1.87 | 4.20 | 2.02 | ||
CPR Croissance Reactive i | 1.02B | 1.71 | 3.60 | 2.13 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review